Multi-Protein Signature for Type 2 Diabetes Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic criteria for type 2 diabetes rely heavily on blood glucose levels and glycated hemoglobin (HbA1c), failing to account for the complex systemic alterations associated with the disease, such as obesity, lipid metabolism alterations, hypertension, and chronic inflammation, limiting personalized treatment strategies.
Innovation Solution
A multi-protein signature is developed using differentially expressed proteins in biological samples, integrated with clinical data to predict diabetes status through a logistic regression model, enhancing diagnostic accuracy and personalization of treatment plans.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic criteria using blood glucose levels and HbA1c are used, then diagnostic simplicity is maintained, but diagnostic accuracy and ability to detect complex systemic alterations deteriorates
Solution Approach 1:
The diagnostic approach is segmented into multiple independent protein marker measurements (adiponectin, albumin, apolipoproteins, complement factors, coagulation factors, fibrinogen, haptoglobin, and SAA) rather than relying on a single glucose or HbA1c measurement. Each protein marker provides specific information about different aspects of diabetes pathology including inflammation, metabolism, and coagulation status.
Solution Approach 2:
Multiple protein marker measurements are merged into a comprehensive diagnostic panel that evaluates various physiological systems simultaneously. The combination of markers from different functional categories (inflammatory markers like SAA and complement factors, metabolic markers like apolipoproteins and adiponectin, and coagulation markers like fibrinogen and factor VII) creates a holistic view of disease status.
2Adaptability or versatility
If only blood glucose and HbA1c are measured, then test cost and time are reduced, but ability to stratify diabetes phenotypes and personalize treatment deteriorates
Solution Approach 1:
Instead of measuring all possible biomarkers, the invention selectively measures a specific panel of 10 protein markers that have been identified as most relevant to diabetes pathology and phenotype stratification. This partial action approach provides sufficient information for personalized medicine without the excessive time and cost of comprehensive proteomic analysis.
3Reliability
If a comprehensive multi-protein panel is used, then diagnostic accuracy and personalization are improved, but test complexity and cost increase
Solution Approach 1:
The invention changes the measurement parameters from traditional glucose-centric metrics to a protein-based panel that captures different physiological dimensions. By selecting proteins with specific functional roles in diabetes pathophysiology, the assay achieves higher reliability in predicting disease status and response to treatment while maintaining a manageable complexity level through focused marker selection.
Data Source
AI summary
Provided herein is a method for determining a type 2 diabetes status in a subject, where the method includes obtaining a biological sample from the subject; determining the level of one or more proteins; and transforming the weighted sum of the levels of one or more proteins into a probability score, wherein an increase in the probability score indicates an increased likelihood of the type 2 diabetes status.